Oral News and Research

RSS

Expanded vaccine supply allows resumption of cholera prevention campaigns

Global cholera vaccine supply has now increased to a level sufficient to allow the resumption of life-saving preventive campaigns for the first time in over three years, Gavi, the Vaccine Alliance, UNICEF, and the World Health Organization (WHO) announced today.

5 Feb 2026

New compound advances body clock independent of dosing time

A collaborative team including Emeritus Professor Tei H. (Kanazawa University), Associate Professor Takahata Y. (Osaka University), Professor Numano R. (Toyohashi University of Technology), and Associate Professor Uriu K. (Institute of Science Tokyo) discovered that Mic-628 selectively induces the mammalian clock gene Per1.

4 Feb 2026

Clear aligners protect oral microbiome better than fixed braces

Researchers compare the effects of clear aligners and fixed appliances on oral microbiota and oxidative stress in the oral cavity.

4 Feb 2026

MRI scans reveal human brain growth from pregnancy through birth

Analyzing brain growth across pregnancy and early life, this study offers new insights into sex-specific development and its implications for neurodevelopment.

3 Feb 2026

Solvent-free method improves drug solubility using mesoporous silica

A large share of medicines developed today may never reach patients for a surprisingly simple reason: they cannot dissolve well enough in water.

31 Jan 2026

Palbociclib improves progression-free survival in HER2 positive breast cancer

PrECOG, LLC, today announced the publication of final results from the pivotal phase 3 PATINA study in the New England Journal of Medicine (NEJM).

30 Jan 2026

Microneedle patches enhance acne treatment with dual drug delivery

Acne vulgaris affects a large proportion of adolescents and young adults and can lead to long-term scarring and psychological distress.

30 Jan 2026

Oral cancer pain and opioid tolerance share a common EGFR mechanism

Epidermal growth factor receptor (EGFR) signaling in the tissue around oral cancers both increases nerve sensitivity and makes opioids less effective, according to new research published in Science Signaling.

29 Jan 2026

Study reveals a link between oral microbiota and cognitive performance in schizophrenia

An association between oral microbiota and cognitive performance in schizophrenia has been reported by researchers at Science Tokyo.

29 Jan 2026

Combination therapy improves cognition in Alzheimer’s models

In recent years, research into cannabis and its main psychoactive ingredient, Δ⁹-tetrahydrocannabinol (THC), has unearthed medical benefits including anti-inflammatory and neuroprotective properties.

28 Jan 2026

Newly discovered compound can advance the body's internal clock

A Japanese research team has discovered a new compound that can advance the body's internal clock—offering hope for faster recovery from jet lag and better adaptation to night-shift work.

28 Jan 2026

PFOA exposure disrupts hormone signaling and impairs embryo implantation in mice

A new experimental study has found that perfluorooctanoic acid (PFOA), a widely used industrial chemical, can interfere with key biological processes required for successful embryo implantation, raising concerns about its potential impact on female fertility.

27 Jan 2026

How modern lifestyles reprogram the gut microbiome and shape disease risk

Modern lifestyle factors such as circadian disruption, sleep deprivation, stress, and exercise reshape the gut bacteriome and its metabolic outputs. These microbiome changes are linked to immune, metabolic, and cancer-related pathways, largely through evidence from animal models and observational human studies.

27 Jan 2026

Reducing alcohol consumption could ease Australia’s cancer burden

National data indicates that lowering alcohol consumption could prevent thousands of cancer deaths, emphasizing the importance of public health interventions.

27 Jan 2026

Tiny plastic particles may interfere with brain processes implicated in Parkinson’s disease

Micro- and nanoplastics are increasingly detected in human tissues, including the brain, and experimental evidence suggests they can interact with biological pathways central to Parkinson’s disease pathology. This review synthesises mechanistic data indicating that plastic particles may influence protein aggregation, neuroinflammation, mitochondrial dysfunction, and the gut–brain axis, while emphasising the need for prospective human studies.

26 Jan 2026

New role for GLP-1 drugs: Improving survival in people with severe psychiatric disorders

This editorial argues that GLP-1 receptor agonists could substantially improve healthspan and reduce premature mortality in people with serious mental illnesses by targeting cardiometabolic risk rather than psychiatric symptoms alone. It highlights emerging evidence, safety considerations, and equity challenges that position GLP-1 RAs as a promising public health strategy for this high-risk population.

25 Jan 2026

Unraveling liver injury mechanisms in familial hypobetalipoproteinemia

Familial Hypobetalipoproteinemia (FHBL), caused by variants in the apolipoprotein B (APOB) gene, is a rare autosomal co-dominant monogenic disorder characterized by lifelong low plasma levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), and APOB.

24 Jan 2026

Blood-based epigenetic signatures enable early risk assessment in prediabetes

Prediabetes is an extremely heterogeneous metabolic disorder. Scientists from several partner institutes of the German Center for Diabetes Research (DZD) have now used artificial intelligence (AI) to identify epigenetic markers that indicate an elevated risk of complications.

24 Jan 2026

AI-designed NLRP3 inhibitor receives FDA clearance for Parkinson disease trials

Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), today announced that ISM8969, an orally available NLRP3 inhibitor targeting inflammation and neurodegenerative disorders, has recently received investigational new drug (IND) clearance from the U.S. Food and Drug Administration (FDA), intended for the treatment of Parkinson's Disease.

23 Jan 2026

Peptide-based platform marks a major step toward needle-free diabetes care

For more than a century, oral insulin has been considered a "dream" therapy for diabetes, hindered by enzymatic degradation in the digestive tract and the absence of a dedicated intestinal transport mechanism. Consequently, many patients must rely on daily insulin injections, which can significantly reduce their quality of life.

23 Jan 2026